



BD, Accelerate Diagnostics Announce Global Commercial Collaboration

August 15, 2022

Companies will work together to bring rapid antimicrobial identification and susceptibility diagnostics to more clinicians and patients worldwide

FRANKLIN LAKES, N.J. and TUCSON, Ariz., Aug. 15, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in-vitro diagnostics in microbiology, today announced a worldwide commercial collaboration agreement where BD will offer Accelerate's rapid testing solution for antibiotic resistance and susceptibility offering results in hours, versus one to two days with some traditional laboratory methods.



Under the agreement, BD will market and sell the Accelerate Pheno[®] system and Accelerate Arc[™] module and associated test kits through its global sales network in territories where products have regulatory approval or registration. These solutions complement BD's existing Clinical Microbiology portfolio and advance the shared goal of both companies to address the global threat of antimicrobial resistance.

"When a patient is very sick, every minute matters," said Brooke Story, president of Integrated Diagnostic Solutions for BD. "Rapid testing can quickly determine if an antibiotic should be used for treatment, and if so, which one. Through our collaboration with Accelerate Diagnostics, we can help clinicians more quickly, efficiently and effectively treat patients, which may lead to a reduction in health care costs and help slow the spread of antimicrobial resistance."

The Accelerate PhenoTest[®] BC kit is the first test cleared by the U.S. Food and Drug Administration that can deliver both rapid identification and phenotypic antibiotic susceptibility results in hours direct from positive blood cultures. Recent external studies indicate this solution offers results one to two days faster than traditional laboratory methods, which can include culturing samples for 18 to 24 hours, and then performing a susceptibility test that can take eight to 24 hours to result. This enables clinicians to optimize antibiotic selection and dosage specific to the individual patient, days earlier. It is well established in peer-reviewed literature that improving time to optimal therapy benefits both patient outcomes and hospital operations.

The Accelerate Arc[™] module is a simple load-and-go system that eliminates the requirement of a subculture for MALDI ID as well as the need for lengthy hands-on time by automating the direct MALDI ID workflow. It is currently US , CE-IVDR and UKCA registered for positive blood cultures.

"With BD's large installed customer base of clinical microbiology systems, this collaboration exponentially increases our global commercial reach and provides numerous ways to increase our market penetration with Pheno and Arc to reach more clinicians and patients," said Jack Phillips, president and CEO of Accelerate Diagnostics. "Beyond the immediate clinical and commercial benefits, we are excited about the opportunity to collaborate with BD as a long-term leader in clinical microbiology."

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistant infections, a leading cause of sepsis. The company's first fully automated platform to provide rapid identification and antimicrobial susceptibility results remains the only solution currently cleared for use with positive blood culture samples by the U.S. FDA.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Contacts

Media	Investors
Troy Kirkpatrick	Francesca DeMartino

VP, Public Relations SVP, Head of Investor Relations
858.617.2361 201.847.5743
troy.kirkpatrick@bd.com francesca.demartino@bd.com

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/bd-accelerate-diagnostics-announce-global-commercial-collaboration-301605434.html>

SOURCE BD (Becton, Dickinson and Company)